Drug Trial Radar · NCT07807995
A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
605
Planned (sponsor's estimate)
Start
Sep 17, 2026
Primary completion
Dec 28, 2029
Study completion Dec 28, 2029
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Sep 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).
Conditions
- Immunoglobulin A Nephropathy
Interventions
PovetaciceptDrug
Subcutaneous injection administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 up to Week 112
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Western Nephrology - Arvada
Arvada, Colorado
CTR Oakwater, LLC
Orlando, Florida
Idaho Kidney Institute- Idaho Falls
Idaho Falls, Idaho
Prolato Clinical Research Center - Kirby Dr
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.